Researcher

    Carolina Alfieri , Ph.D.

    carolina.alfieri@recherche-ste-justine.qc.ca
    Carolina Alfieri
    Research Axis
    Viral and Immune Disorders and Cancers
    Research Theme
    Infection and immunity
    Address
    CHUSJ - Centre de Recherche

    Phone
    514 345-4931 #6135

    Fax
    514 345-4801

    Career Summary

    Our research has focused on the biology of Epstein-Barr virus (EBV) infection and EBV-induced B-cell lymphoproliferation in immunocompromised patients. Our laboratory was the first to demonstrate a direct correlation between EB viral load and development of post-transplant lymphoproliferative disease (PTLD). This finding has had an important impact on the diagnosis/prognosis and pre-emptive management of PTLD. A follow-up study demonstrated that a second marker can be used in conjunction with EB viral load to better define patients at high risk for PTLD. More recently, our laboratory has developed a deoxyribozyme antiviral with catalytic activity against the hepatitis C virus (HCV). This deoxyribozyme was shown to cleave HCV RNA efficiently in cells transfected with the full-length HCV genome. In vivo collaborative studies using an infectious mouse model are now in progress to investigate the potential clinical application of our deoxyribozyme.

Publications

Inhibition of I?B kinase by thalidomide increases hepatitis C virus RNA replication - Rance E, Tanner J, Alfieri C. Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication. J Viral Hepat 2012; 19(2): e73-80.

Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children - Trottier H, Buteau C, Robitaille N, Duval M, Tucci M, Lacroix J, Alfieri C. Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children. Transfusion 2012; 52(12): 2653-2663.

Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation - Merindol N, Salem Fourati I, Brito RM, Grenier A, Charrier E, Cordeiro P, Caty M, Mezziani S, Malette B, Duval M, Alfieri C, Ovetchkine P, Le Deist F, Soudeyns H. Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation. J Immunol 2012; 189(10): 5016-5028.

Reduction in intracellular HCV RNA and virus protein expression in human hepatoma cells following treatment with 2'-O-methyl-modified anti-core deoxyribozyme - Trépanier J, Tanner J, Alfieri C. Reduction in intracellular HCV RNA and virus protein expression in human hepatoma cells following treatment with 2'-O-methyl-modified anti-core deoxyribozyme. Virology 2008; 377(2): 339-344.

Atypical Epstein-Barr virus (EBV) latent protein expression in EBV-associated smooth muscle tumours occurring in paediatric transplant recipients - Rougemont A-L, Alfieri C, Fabre M, Gorska-Flipot I, Papp E, Champagne J, Phan V, Fournet JC, Sartelet H. Atypical Epstein-Barr virus (EBV) latent protein expression in EBV-associated smooth muscle tumours occurring in paediatric transplant recipients. Histopathology 2008; 53(3): 363-367.

Prevention of CMV disease in pediatric kidney transplant recipients: Evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune prophylaxis in high-risk patients - Renoult E, Clermont MJ, Phan V, Buteau C, Alfieri C, Tapiero B. Prevention of CMV disease in pediatric kidney transplant recipients: Evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune prophylaxis in high-risk patients. Pediatr Transplant 2008; 12(4): 420-425.

Cleavage of intracellular hepatitis C RNA in the virus core protein region by deoxyribozymes - Trépanier J, Tanner J, Momparler RL, Le NLO, Alvarez F, Alfieri C. Cleavage of intracellular hepatitis C RNA in the virus core protein region by deoxyribozymes. J Viral Hepat 2006; 13(2): 131-138.

Oligonucleotide-based therapeutic options against hepatitis C virus infection - Trépanier J, Tanner J, Alfieri C. Oligonucleotide-based therapeutic options against hepatitis C virus infection. Antivir Therap 2006; 11(3): 273-287.

Book review: Epstein-Barr virus - Alfieri C. Book review: Epstein-Barr virus. Clin Infect Dis 2006; 43(5): 669.

Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro - Kotsiopriftis M, Tanner J, Alfieri C. Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro. J Virol 2005; 79(11): 7255-7261.

Epstein-Barr virus (EBV) early-antigen antibody testing and blood EBV DNA load in posttransplantation lymphoproliferative disease (reply to 32891) - Alfieri C. Epstein-Barr virus (EBV) early-antigen antibody testing and blood EBV DNA load in posttransplantation lymphoproliferative disease (reply to 32891). J Infect Dis 2004; 190(8): 1525-1526.

Epstein-Barr virus early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease - Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C. Epstein-Barr virus early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis 2003; 188(12): 1853-1864.

Epstein-Barr virus infection in transplant recipients: summary of a workshop on surveillance, prevention and treatment - Allen U, Alfieri C, Preikasaitis JK, Humar A, Moore D, Tapiero B, Tellier R, and the Canadian PTLD workshop group. Epstein-Barr virus infection in transplant recipients: summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis 2002; 13(2): 89-96.

The Epstein-Barr virus and post-transplant lymphoproliferative disease : interplay of immunosuppression, EBV and the immune system in the development of disease pathogenesis - Tanner J, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease : interplay of immunosuppression, EBV and the immune system in the development of disease pathogenesis. Transpl Infect Dis 2001; 3(2): 60-69.

Activation of transcription factors NFkB and NF-IL-6 by the human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 - Roux P, Alfieri C, Cohen E, Hrimech M, Tanner J. Activation of transcription factors NFkB and NF-IL-6 by the human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8. J Virol 2000; 74(10): 4658-4665.

Epstein-Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T cell apoptosis - Tanner J, Alfieri C. Epstein-Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T cell apoptosis. Blood 1999; 94: 3439-3447.

Chronic active Epstein-Barr virus infections (review) - Alfieri C, Rousseau E, Tanner J. Chronic active Epstein-Barr virus infections (review). HERPES 1998; 5: 12-14.

Natural history of Epstein-Barr virus infection in a prospective pediatric cohort born to HIV-infected mothers - Pedneault L, Lapointe N, Alfieri C, Ghadirian P, Carpentier L, Samson J, Joncas J. Natural history of Epstein-Barr virus infection in a prospective pediatric cohort born to HIV-infected mothers. J Infect Dis 1998; 177: 1087-1090.

Antibody and antibody-dependent cellular cytotoxicity (ADCC) against the BamHI A rightward open reading frame-1 (BARF1) protein of Epstein-Barr virus (EBV) in EBV-associated disorders - Tanner J, Wei MX, Alfieri C, Ahmad A, Tailor P, Ooka T, Menezes J. Antibody and antibody-dependent cellular cytotoxicity (ADCC) against the BamHI A rightward open reading frame-1 (BARF1) protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J Infect Dis 1997; 175: 38-46.

Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection - Tanner J, Diaz-Mitoma F, Rooney C, Alfieri C. Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection. J Infect Dis 1997; 176: 1454-1461.

Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx - Alfieri C, Tanner J, Carpentier L, Perpête C, Savoie A, Paradis K, Delage G, Joncas J. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 1996; 87: 812-817.

Induction of interleukin-6 following stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350/220 - Tanner J, Alfieri C, Chatila TA, Diaz-Mitoma F. Induction of interleukin-6 following stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350/220. J Virol 1996; 70: 570-575.

Interactions involving cyclosporine A, interleukin-6 and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease - Tanner J, Alfieri C. Interactions involving cyclosporine A, interleukin-6 and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Leuk Lymphoma 1996; 21: 379-390.

Diagnosis of cytomegalovirus (CMV) infection in pediatric transplant patients by the antigenemia, shell vial and conventional culture assays done on blood: correlation with CMV disease - Pedneault L, Anglow M, Alfieri C, Rubin E. Diagnosis of cytomegalovirus (CMV) infection in pediatric transplant patients by the antigenemia, shell vial and conventional culture assays done on blood: correlation with CMV disease. J Clin Diag Virol 1996; 6: 51-61.

Antibody responses against two Epstein-Barr virus nuclear antigens (EBNA1 and EBNA2) during EBV primary infection in children born to HIV-infected mothers - Pedneault L, Lapointe N, Alfieri C, Ghadirian P, Carpentier L, Samson J, Joncas J. Antibody responses against two Epstein-Barr virus nuclear antigens (EBNA1 and EBNA2) during EBV primary infection in children born to HIV-infected mothers. Clin Infect Dis 1996; 23: 806-808.

About this page
Edited by Hoffmann Maude

Created on 9/18/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine